Last week saw a slight dip in the FTSE mid week before rising to close the week at 6,163 points (having opened at 6,122). The AIM All share ended the week where it started at 735 points. UK Retail Sales figures were announced on Friday, which fell at a seasonally adjusted 0.1 per cent in December from the month before, whilst US Retail Sales on the other hand in December were up 0.5 per cent, and compared with the prior year were 4.7 per cent up. UK and Eurozone inflation figures both came in at 2.7 per cent. This week has seen President Obama inaugurated for a second term, where he outlined his economic plans, including tackling problems such as the fast growing net-debt (as a result of retirees), crumbling infrastructure and need for education/training. Back in the Eurozone, the difficulties continue, where France for example has seen continuing unemployment problems (with a rate of 10.3 per cent having risen for 19 consecutive months to approach a 15-year high), and which doesn’t look to be helped by an agreement to allow companies to cut work time and pay as demand slows, and extending benefits and raising a tax on employers. The week ahead sees UK December unemployment figures, IMF World Economic Outlook update and UK GDP Q4 first estimate being announced, and the World Economic Forum in Davos also commences.
ABC Half Year Trading Update, ALK Trading update, ATC Lease Option, BNO agreement with Telefónica and trading update, BMY Interim Management Statement, BGL Prefeasibility Study, CAP Funding Award, CGNR Excellent flotation results, CNS Trading update, CRW Trading update, EKF Trading update, EVO Bid situation, FIP Diurnal enrolls first patient into trial, IDEA Healthcare Contract Wins and New Appointments, INTQ Trading Update, NET trading update, NEW Drilling Update, NYO Drilling and Trading update, PRM Trading Statement, RTG Trading update, SVR Trading update, SQS Trading update, SUN to benefit from £5.05m RGF Grant, SYM Trading Update, TRS Indonesian acquisition, THAL Ecuador Contract, Wipes approval in China
Abcam (LON:ABC 363p/£720.90m) Abcam, a global leader in the supply of protein research tools, this morning announced a trading update ahead of its results for the six months ended 31 December 2012. The business has performed well despite the continued pressures on centrally funded research budgets. In the US, which is the largest market, the postponement of a federal decision on…
This document should not be relied upon as being an impartial or objective assessment of the subject matter and is not deemed to be "independent research" for the purposes of the Financial Services Authority (FSA) rules. As a consequence the research (a) has not been prepared in accordance with legal requirements designed to promote the independence of investment research; and (b) is not subject to any prohibition on dealing ahead of the dissemination of investment research (although Hybridan does impose restrictions on personal account dealing in the run up to publishing research as set out in our Conflicts of Interest Policy).
The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual partners and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document.
This document has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments. The information contained herein is based on materials and sources that we believe to be reliable, however, Hybridan LLP makes no representation or warranty, either express or implied, in relation to the accuracy, completeness or reliability of the information contained herein. Opinions expressed are our current opinions as of the date appearing on this material only. Any opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. None of Hybridan LLP, its affiliates or employees shall have any liability whatsoever for any indirect or consequential loss or damage arising from any use of this document.
In the UK, this report is directed at and is for distribution only to persons who (i) fall within Article 19(1) (persons who have professional experience in matters relating to investments) or Article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc) of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005 (as amended) or (ii) are Professional Clients or Eligible Counterparties of Hybridan LLP (all such persons together being referred to as "relevant persons"). This report must not be acted on or relied up on by persons in the UK who are not relevant persons.
Neither this report nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this report comes should inform themselves about, and observe any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of UK or US securities law, or the law of any such other jurisdictions.
Investments in general involve some degree of risk, including the risk of capital loss. The services, securities and investments discussed in this document may not be available to or suitable for all investors. Investors should make their own investment decisions based upon their own financial objectives and financial resources and, if in any doubt, should seek advice from an investment advisor. Past performance is not necessarily a guide to future performance and an investor may not get back the amount originally invested. Where investment is made in currencies other than the investor?s base currency, movements in exchange rates will have an effect on the value, either favourable or unfavourable. Levels and bases for taxation may change. When Hybridan LLP comments on AIM or PLUS Markets shares investors should be aware that because the rules for those markets are less demanding than the Official List of the London Stock Exchange the risks are higher. Furthermore, the marketability of these shares is often restricted.
Hybridan LLP and/or its associated companies may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the partners, directors and employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests. Neither the whole nor any part of this material may be duplicated in any form or by any means. Neither should any of this material be redistributed or disclosed to anyone without the prior consent of Hybridan LLP. Hybridan LLP is Authorised and Regulated by the Financial Services Authority and is a member of the London Stock Exchange.
29 Throgmorton Street, London EC2N 2AT
If you would like to receive other research reports from Hybridan, or would like to unsubscribe, please e- mail firstname.lastname@example.org, title e-mail "research reports" or "unsubscribe me" Hybridan LLP is authorised and regulated by the Financial Services Authority Member of the London Stock Exchange